| 高俊,安新江,吴中梅.磷酸肌酸与免疫球蛋白联合治疗病毒性心肌炎病儿对心功能及免疫学指标的影响[J].安徽医药,2024,28(1):198-201. |
| 磷酸肌酸与免疫球蛋白联合治疗病毒性心肌炎病儿对心功能及免疫学指标的影响 |
| Effects of combined treatment with phosphocreatine and immunoglobulin on cardiac func- tion and immunological indexes in children with viral myocarditis |
| |
| DOI：10.3969/j.issn.1009-6469.2024.01.042 |
| 中文关键词: 心肌炎 病毒性疾病 磷酸肌酸 免疫球蛋白 心功能 免疫学指标 |
| 英文关键词: Myocarditis Virus diseases Creatine phosphate Immunoglobulin Heart function Immunological index |
| 基金项目:徐州市科技项目( KC19033) |
|
| 摘要点击次数: 216 |
| 全文下载次数: 105 |
| 中文摘要: |
| 目的通过联合磷酸肌酸与免疫球蛋白治疗，分析其对病毒性心肌炎( VM)病儿心功能及免疫学指标的影响。方法选取徐州市儿童医院 2018年 6月至 2021年 6月收治 VM病儿 104例为研究对象，按照随机数表法分为观察组和对照组(各 52例)。对照组采用磷酸肌酸方案，观察组采用磷酸肌酸与免疫球蛋白联合方案。比较两组临床疗效、治疗前后心功能评分及免疫学指标水平。结果观察组临床总有疗率 79.07%高于对照组 58.14%(P<0.05)。治疗后，观察组心室射血分数(EF)(73.15±7.26)%、心室短轴缩短率( FS)(35.15±5.00)%、二尖瓣舒张早期血流速度峰值与二尖瓣舒张晚期血流速度峰值的比值( VA/TE)(0.51±0.40)分，对照组( 63.12±6.28)分、(28.75±4.43)分、(0.62±0.08)分，观察组升高或降低程度更为显著，优于对照组( P<0.05)。治疗后，观察组 CD3+(71.35±6.16)%、CD4+(49.82±6.12)%、CD8+(18.76±2.38)%、CD4+/CD8+(2.68±0.34)%，对照组(59.54±4.26)%、(39.65±2.79)%、(22.36±2.99)%、(1.78±0.23)%，观察组优于对照组( P<0.05)。治疗后，两组心肌损伤标志物均下降，观察组优于对照组( P<0.05)。结论通过磷酸肌酸与免疫球蛋白联合治疗 VM，临床效果显著，可以有效恢复 VM病儿心功能，提高 VM病儿免疫功能，临床应用价值较高。 |
| 英文摘要: |
| Objective Combination of phosphocreatine and immunoglobulin was used to treat viral myocarditis (VM), and its effecton cardiac function and immunological indicators was analyzed.Methods A total of 104 VM patients admitted to Xuzhou Children'sHospital from June 2018 to June 2021 were selected as the research subjects, and were divided into the observation group and the con-trol group (52 cases each) according to the random number table method. The control group was given with phosphocreatine regimen,and the observation group was given with a combination regimen of phosphocreatine and immunoglobulin. The clinical efficacy, cardiacfunction scores and immunological index levels before and after treatment were compared between the two groups.Results The total clinical effective rate in the observation group was 79.07%, which was higher than 58.14% in the control group (P<0.05). After treat-ment, ventricular ejection fraction (EF) was (73.15 ± 7.26)%, ventricular short axis shortening rate (FS) was (35.15 ± 5.00)%, the ratioof peak blood flow velocity in early mitral diastole to peak blood flow velocity in late mitral diastole (VA/TE) was (0.51 ± 0.40) in the ob-servation group, (63.12 ± 6.28), (28.75 ± 4.43), (0.62 ± 0.08) in the control group, the increase or decrease of the observation group wasbetter than that of the control group (P<0.05). After treatment, CD3+ (71.35 ± 6.16)%, CD4+ (49.82 ± 6.12)%, CD8+ (18.76 ± 2.38)%, CD4+ / CD8+ (2.68 ± 0.34)%, control group (59.54 ± 4.26)%, (39.65 ± 2.79)%, (22.36 ± 2.99)%, (1.78 ± 0.23)%, the observation groupwas better than the control group (P<0.05).After treatment, the markers of myocardial injury decreased in both groups, and the observa-tion group was more significant than the control group (P<0.05).Conclusion The combination of phosphocreatine and immunoglobu-lin in the treatment of VM has significant clinical effects, which can effectively restore the heart function of children with VM, and im-prove the immune function of children with VM, with high clinical application value. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
